Professor of Medicine, UCSF
Neurosurgery
Dr. Susan M. Chang, MD
|
|
Give Review
Susan Chang practices Neurosurgery. She received 3 awards: "America's Top Doctors", "America's Top Doctors for Cancer" and "CMS Meaningful Use Stage 1 Certification". Susan M. Chang, MD is a published MD. She published 99 publications, including: 'Autophagy Modulates Cell Mineralization on Fluorapatite-Modified Scaffolds.' She is registered with Medicare.
Publications
- Magnetic resonance analysis of malignant transformation in recurrent glioma.
- Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience.
- Evolution of DNA repair defects during malignant progression of low-grade Gliomas after temozolomide treatment.
- Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotin...
- Simultaneous imaging of radiation-induced cerebral microbleeds, arteries and veins, using a multiple gradient echo sequence at 7 Tesla.
- Fluorapatite-modified Scaffold on Dental Pulp Stem Cell Mineralization.
- Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).
- Impact of imaging measurements on response assessment in glioblastoma clinical trials.
- Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk.
- Short-echo three-dimensional H-1 MR spectroscopic imaging of patients with glioma at 7 tesla for characterization of differences in metabolite levels.
- Phase II Trial of 7days on/7 days off temozolmide for recurrent high-grade glioma.
- Response of primary glioblastoma cells to therapy is patient specific and independent of Cancer stem cell phenotype.
- Characterization of metabolites in infiltrating Gliomas using ex vivo (1) H high-resolution magic angle spinning spectroscopy.
- A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
- Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma.
- Susceptibility-weighted MR imaging of radiation therapy-induced cerebral microbleeds in patients with glioma: a comparison between 3T and 7T.
- A first generation compact microbeam radiation therapy System based on carbon nanotube X-ray technology.
- Challenges relating to solid tumour Brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.
- Challenges relating to solid tumour Brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
- Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis.
- Multidisciplinary care of patients with Brain tumors.
- Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.
- Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging.
- Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal Gliomas regardless of grade or histology.
- Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept.
- Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein.
- Endpoints for clinical trials and revised assessment in neuro-oncology.
- Comparison of DSC-MRI post-processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBM.
- Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03.
- Regional variation in histopathologic features of Tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging.
- Automated prescription of oblique Brain 3D magnetic resonance spectroscopic imaging.
- SSBP2 Variants Are Associated with Survival in Glioblastoma Patients.
- The superiority of conservative resection and adjuvant radiation for craniopharyngiomas.
- Differential Sensitivity of Glioma- versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors.
- Identifying malignant transformations in recurrent low grade Gliomas using high resolution magic angle spinning spectroscopy.
- Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas.
- (11)C-CHO PET in optimization of target volume delineation and treatment regimens in postoperative radiotherapy for Brain gliomas.
- Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
- 7-Tesla Susceptibility-Weighted Imaging to Assess the Effects of Radiotherapy on Normal-Appearing Brain in Patients with Glioma.
- Conditional Probability of Survival in Patients With Newly Diagnosed Glioblastoma.
- Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme an...
- MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II Gliomas.
- Neurosurgical management and prognosis of patients with glioblastoma that progress during bevacizumab treatment.
- It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology.
- A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival.
- Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study.
- Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas.
- Early childhood stimulation benefits adult competence and reduces violent behavior.
- A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
- Choline metabolism, proliferation, and angiogenesis in nonenhancing grades 2 and 3 Astrocytoma.
- Clinical trial end points for high-grade glioma: the evolving landscape.
- Functional mapping-guided resection of low-grade gliomas in eloquent areas of the Brain: improvement of long-term survival. Clinical article.
- DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.
- Incorporation of biomarker assessment in novel clinical trial designs: personalizing Brain tumor treatments.
- Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
- Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study.
- Impact of bevacizumab chemotherapy on craniotomy wound healing.
- Ex vivo MR spectroscopic measure differentiates Tumor from treatment effects in GBM.
- Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium St...
- Clinical trials in Brain tumor surgery.
- Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
- Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
- Updated response assessment criteria for high-grade Gliomas: response assessment in neuro-oncology working group.
- Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.
- Activation of PI3K/mTOR pathway occurs in most adult low-grade Gliomas and predicts patient survival.
- Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma.
- Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
- Secondary gliosarcoma: a review of clinical features and pathological diagnosis.
- Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.
- Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging.
- Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
- Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article.
- Current perspectives on neuro-oncology.
- End point assessment in Gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.
- Quality of life in adults with Brain tumors: current knowledge and future directions.
- Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma.
- Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular Schwannoma.
- GRAPPA-based susceptibility-weighted imaging of normal volunteers and patients with Brain tumor at 7 T.
- Quality of life in low-grade glioma patients receiving temozolomide.
- Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
- Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy.
- Preoperative prognostic classification System for hemispheric low-grade gliomas in adults.
- CONVECTION-ENHANCED DELIVERY OF CINTREDEKIN BESUDOTOX (INTERLEUKIN-13-PE38QQR) FOLLOWED BY RADIATION THERAPY WITH AND WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED MALIGNANT...
- Comparison of T(1) and T(2) metabolite relaxation times in glioma and normal Brain at 3T.
- Relationship between choline and apparent diffusion coefficient in patients with Gliomas.
- Role of extent of resection in the long-term outcome of low-grade hemispheric Gliomas.
- Development of a robust method for generating 7.0 T multichannel phase images of the Brain with application to normal volunteers and patients with neurological diseases.
- Seizure characteristics and control following resection in 332 patients with low-grade Gliomas.
- Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american Brain tumor co...
- Three-dimensional J-resolved H-1 magnetic resonance spectroscopic imaging of volunteers and patients with Brain tumors at 3T.
- Early childhood stunting is associated with poor psychological functioning in late adolescence and effects are reduced by psychosocial stimulation.
- Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy ma...
- Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.
- Treatment for posterior fossa dissemination of primary supratentorial glioma.
- Autophagy Modulates Cell Mineralization on Fluorapatite-Modified Scaffolds.
Schools
University Of British Columbia Faculty Of Medicine
Procedures Preformed
- Craniectomy, Craniotomy, Surgery of Skull Base, Neuroendoscopy
Conditions Treated
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- Epilepsy
- Hydrocephalus
- View All
Doctors Specialties
- Neurosurgery
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
Hospital
-
San Francisco General Hospital and Trauma Center -
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1346299518 | |
| NPPES Provider LastName | CHANG | |
| NPPES Provider FirstName | SUSAN | |
| NPPES Provider ZIPCode | 941432202 | |
| NPPES Provider State | CA | |
| Specialty Description | Neurology | |
| Total Claim Count | 147.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1346299518 |
| Last Name Of The Provider | CHANG |
| First Name Of The Provider | SUSAN |
| View All |
Similar Doctors
|
|
Dr. Philip R. Weinstein, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Geoffrey T. Manley, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Patrick E. Taylor, MD |
|
|
Dr. Grant E. Gauger, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Corey Raffel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Peter B. Weber, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Tarun Arora, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Phiroz E. Tarapore, MD |
|
|
Dr. Christopher Owen, MD |
|
|
Dr. Corinna C. Zygourakis, MD |
|
|
Dr. Dario J. Englot, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason M. Davies, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Seunggu J. Han, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karine Michaud, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aaron J. Clark, MD |